RAD51B is altered in 0.46% of prostate carcinoma patients [3].

RAD51B is an inclusion criterion in 15 clinical trials for prostate carcinoma, of which 12 are open and 3 are closed. Of the trials that contain RAD51B status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

Olaparib has evidence of efficacy in patients with RAD51B mutation in prostate carcinoma [4].

RAD51B is altered in 0.44% of malignant solid tumor patients [3].

RAD51B is an inclusion criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain RAD51B status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 7 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [4].

RAD51B is altered in 0.24% of breast carcinoma patients [3].

RAD51B is an inclusion criterion in 21 clinical trials for breast carcinoma, of which 17 are open and 4 are closed. Of the trials that contain RAD51B status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [4].

RAD51B is altered in 0.47% of prostate adenocarcinoma patients [3].

RAD51B is an inclusion criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain RAD51B status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [4].

RAD51B is altered in 0.19% of ovarian carcinoma patients [3].

RAD51B is an inclusion criterion in 17 clinical trials for ovarian carcinoma, of which 13 are open and 4 are closed. Of the trials that contain RAD51B status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51B is an inclusion criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain RAD51B status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51B is an inclusion criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain RAD51B status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

RAD51B is altered in 0.39% of adenocarcinoma of the gastroesophageal junction patients [3].

RAD51B is an inclusion criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 1 is closed. Of the trials that contain RAD51B status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.25% of small cell lung carcinoma patients [3].

RAD51B is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51B status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [4].

RAD51B is altered in 0.13% of pancreatic adenocarcinoma patients [3].

RAD51B is an inclusion criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51B status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

RAD51B is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51B status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.09% of endometrial carcinoma patients [3].

RAD51B is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51B status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RAD51B is altered in 0.48% of non-small cell lung carcinoma patients [3].

RAD51B is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51B status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.06% of urothelial carcinoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

RAD51B is altered in 1.19% of soft tissue sarcoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.65% of cervical carcinoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.28% of colorectal carcinoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

RAD51B is altered in 0.16% of high grade ovarian serous adenocarcinoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

RAD51B is altered in 0.13% of pancreatic carcinoma patients [3].

RAD51B is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

RAD51B is altered in 0.69% of squamous cell lung carcinoma patients [3].

RAD51B is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

RAD51B is altered in 0.42% of non-hodgkin lymphoma patients [3].

RAD51B is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

RAD51B is altered in 0.14% of esophageal carcinoma patients [3].

RAD51B is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

RAD51B is altered in 0.3% of head and neck carcinoma patients [3].

RAD51B is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51B is altered in 0.17% of gastrointestinal stromal tumor patients [3].

RAD51B is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RAD51B is altered in 2.08% of rhabdomyosarcoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 2.56% of leiomyosarcoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.4% of melanoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.21% of bladder urothelial carcinoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is altered in 1.73% of mantle cell lymphoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.83% of ampulla of vater carcinoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.62% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.31% of neuroblastoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.29% of colorectal adenocarcinoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.48% of glioma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.21% of diffuse large B-cell lymphoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.27% of malignant intestinal neoplasm patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.45% of malignant central nervous system neoplasm patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is altered in 0.17% of malignant esophagogastric neoplasm patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is altered in 0.2% of biliary tract carcinoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is altered in 0.37% of B-cell non-hodgkin lymphoma patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is altered in 0.28% of malignant ovarian epithelial tumor patients [3].

RAD51B is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD51B is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].